Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

Author: AbergJudith A, AckermanPeter, CahnPedro, CastagnaAntonella, ChabriaShiven, De JesusEdwin, DiazRicardo S, GartlandMargaret, GrinsztejnBeatriz, KozalMichael, KumarPrincy N, LalezariJacob P, LatailladeMax, LatiffGulam H, LlamosoCyril, MolinaJean-Michel, MorenoSantiago, PialouxGilles, PierceAmy, ThompsonMelanie, WangMarcia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.

Overview

This study reports interim analyses through week 96 of the BRIGHTE study, which evaluated the efficacy of fostemsavir versus placebo in heavily treatment-experienced individuals with multidrug-resistant HIV-1. Fostemsavir demonstrated superior efficacy compared to placebo after 8-day functional monotherapy.
Paper Details　
Original Abstract of the Article :
Fostemsavir, a prodrug of the first-in-class attachment inhibitor, temsavir, is indicated for heavily treatment-experienced individuals with multidrug-resistant HIV-1. We previously reported superior efficacy of fostemsavir versus placebo in the randomised cohort of the BRIGHTE study after 8-day fun...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3018(20)30240-X

データ提供：米国国立医学図書館（NLM）

Fighting HIV with Fostemsavir: A New Weapon in the Arsenal

HIV is a complex and challenging disease, like a desert that shifts and changes over time. It's especially challenging for patients who have developed resistance to other treatments, like a sandstorm that has eroded the usual defenses.

Fostemsavir: A New Oasis of Hope

This study investigated the effectiveness and safety of fostemsavir, a new drug designed to fight multidrug-resistant HIV. It's like finding a new water source in the desert, offering hope to those who need it most. Fostemsavir showed promising results, particularly for patients who had not responded to other treatments.

A Beacon of Hope

This study gives hope to patients living with multidrug-resistant HIV. It's like finding a new route through the desert, offering a path to better health. This research is a testament to the relentless efforts of scientists and researchers who are dedicated to finding new ways to fight this challenging disease.

Dr.Camel's Conclusion

This research is a reminder that we can never stop searching for new solutions. It's like exploring a vast and unexplored desert, where we can uncover hidden treasures and new pathways. This study offers a glimpse of hope for the future of HIV treatment, a future that we can all work towards.
Date :
  1. Date Completed 2020-12-18
  2. Date Revised 2022-09-28
Further Info :

Pubmed ID

33128903

DOI: Digital Object Identifier

10.1016/S2352-3018(20)30240-X

Related Literature

Article Analysis
・Effects of fostemsavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.